MtrE Peptide Vaccine for Gonorrhea Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current prevention strategies for gonorrhea are limited, and the emergence of antibiotic resistance in Neisseria gonorrhoeae poses a significant threat, necessitating the development of an effective vaccine.
Innovation Solution
The use of isolated MtrE peptides, specifically those with amino acid sequences at least 80% identical to residues 23-467, 23-155, or 313-467 of SEQ ID NO:1, to produce immunogenic compositions that can immunize against Neisseria gonorrhoeae, targeting the MtrC-MtrD-MtrE active efflux pump system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current prevention strategies (safe-sex counseling and treatment of infected individuals) are used, then implementation is straightforward, but effectiveness is limited due to rapid antibiotic resistance emergence
Solution Approach 1:
The patent applies preliminary action by developing a vaccine that prevents gonorrhea infection before it occurs, rather than relying on treatment after infection. The MtrE peptide vaccine primes the immune system in advance to recognize and combat N. gonorrhoeae, addressing the limitation of current strategies that only treat infected individuals after antibiotic resistance has already compromised treatment effectiveness.
2Reliability
If antibiotics are used to treat gonorrhea, then bacterial infections are eliminated, but antibiotic resistance emerges rapidly reducing treatment effectiveness
Solution Approach 1:
The patent converts the harmful effect of antibiotic resistance into a benefit by targeting the MtrCDE efflux pump system that bacteria use to resist antibiotics. By developing a vaccine against MtrE, a critical component of this resistance mechanism, the invention turns the bacteria's survival strategy into a vulnerability that the immune system can exploit, thereby overcoming antibiotic resistance rather than being hindered by it.
Solution Approach 2:
The MtrE peptide serves as an intermediary target between the immune system and the bacterial resistance mechanism. Rather than directly combating antibiotic resistance or treating infections, the vaccine uses MtrE as a mediator that, when recognized by the immune system, disables the efflux pump system and thereby neutralizes the resistance mechanism, allowing for effective prevention without antibiotic pressure.
3Ease of manufacture
If MtrC and MtrD are targeted, then periplasmic and inner membrane functions are affected, but outer membrane targeting via MtrE provides better vaccine accessibility
Solution Approach 1:
The patent applies the extraction principle by isolating and targeting only the MtrE subunit, which is located in the outer membrane and more accessible to the immune system, rather than attempting to target the entire MtrCDE complex or the less accessible MtrC and MtrD components. This extraction of the most accessible and critical component enables effective vaccine development while simplifying production requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MtrE peptides induce a specific immune response, demonstrating bactericidal activity against gonococcal strains and inhibiting the pump function, providing a potential solution to the growing antibiotic resistance issue.
Implementation Method 1
an antibody or antibody fragment that binds a MtrE protein in Neisseria gonorrhoeae (N. gonorrhoeae)
Implementation Method 2
inhibiting the pump function, providing a potential solution to the growing antibiotic resistance issue
Data Source
AI summary
The invention is directed to MtrE peptides and their use in gonorrhea vaccines.